Published: 5 October 2017
Author(s): Andrea Rubboli
Issue: October 2017
Section: Letter to the Editor

In line with the results of the PIONEER AF-PCI trial with rivaroxaban [1], those of the recent RE-DUAL PCI trial with dabigatran [2] further support the superior safety on bleeding events of dual therapy with a non-vitamin K-antagonist oral anticoagulant (NOAC) plus clopidogrel over conventional triple therapy with warfarin, aspirin and clopidogrel in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention with stent (PCI) (Table 1). From the RE-DUAL PCI trial [2] some additional considerations regarding the independent role of the strategy (i.e., dual vs.

Newsletters

Stay informed on our latest news!